Cannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy?

Basit Öğe Kaydı
dc.authorid0000-0002-7914-188Xen_US
dc.authorid0000-0002-2193-8386en_US
dc.authorid0000-0002-0988-9462en_US
dc.authorid0000-0002-4090-7227en_US
dc.authorid0000-0003-4165-6631en_US
dc.authorid0000-0003-4493-8538en_US
dc.authorid0000-0001-6160-5626en_US
dc.contributor.authorOnay, Ahmet
dc.contributor.authorErtaş, Abdulselam
dc.contributor.authorSüzerer, Veysel
dc.contributor.authorYener, İsmail
dc.contributor.authorYılmaz, Mustafa Abdullah
dc.contributor.authorAyaz-Tilkat, Emine
dc.contributor.authorEkinci, Remzi
dc.contributor.authorBozhan, Nesrin
dc.contributor.authorİrtegun-Kandemir, Sevgi
dc.date.accessioned2021-09-16T06:26:28Z
dc.date.available2021-09-16T06:26:28Z
dc.date.issued2021en_US
dc.departmentDicle Üniversitesi, Fen Fakültesi, Biyoloji Bölümüen_US
dc.descriptionWOS:000691376800017
dc.description.abstractAbstract: To combat the coronaviruses and their novel variants, therapeutic drugs and the development of vaccines that are to be effective throughout human life are urgently needed. The endocannabinoid system (ECS) acts as a modulator in the activation of the microcirculation, immune system, and autonomic nervous system, along with controlling pharmacological functions such as emotional responses, homeostasis, motor functions, cognition, and motivation. The ECS contains endogenous cannabinoids, cannabinoid receptor (CBRs), and enzymes that regulate their biosynthesis, transport, and degradation. Moreover, phytocannabinoids and synthetic cannabinoids that mimic the action of endocannabinoids also play an essential role in the modulation of the ECS. Cannabinoids, the main constituents of cannabis (Cannabis sativa L.), are therapeutic compounds that have received international attention in the health field due to their therapeutic properties. Recently, they have been tested for the treatment of COVID-19 due to their antiviral properties. Indeed, cannabinoid-type compounds, and in particular cannabidiol (CBD), isolated from glandular trichomes found in the calyx of cannabis flowers with reported antiviral properties is hypothesized to be a therapeutic option in the ministration of SARS-CoV-2 consorted with COVID-19 disease. The relevant articles were determined from the database search published mainly in Web of Science, Google scholar, PubMed, Crossref, and ClinicalTrials.gov database during the pandemic period. The articles were evaluated for the therapeutic potentials, mechanisms of action of cannabinoids, the roles of the ECS in the immune system, impact of cannabinoids in SARS-CoV-2 septic, especially if they address the application of cannabinoids as drugs for the curability and management of SARSCoV-2 and its novel variants. Although the evidence needed to be considered using cannabinoids in the control and treatment of viral diseases is currently in its infancy, they already offer an opportunity for clinicians due to their effects in relieving pain, improving appetite, and improving childhood epilepsy, especially in cancer and human immunodeficiency virus (HIV/AIDS) patients. In addition to these, the most recent scientific evidence emphasizes their use in the treatment of the coronavirus infected patients. In brief, all preclinic and clinic studies that have been reported show that, through the cannabinoid system, cannabinoids, particularly CBD, have many mechanisms that are effective in the treatment of patients infected by SARS-CoV-2. Thus, more extensive studies are necessary in this area to fully identify the effects of cannabinoids on SARS-CoV-2.en_US
dc.identifier.citationOnay, A., Ertaş, A., Süzerer, V., Yener, İ., Yılmaz, M.A., Ayaz-Tilkat, E. ve diğerleri. Cannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy? Turkish Journal of Biology, 5(4), 570-587. (Special Issue SI)en_US
dc.identifier.doi10.3906/biy-2105-73
dc.identifier.endpage587en_US
dc.identifier.issn1300-0152
dc.identifier.issn1303-6092
dc.identifier.issue4 SIen_US
dc.identifier.pmid34803455
dc.identifier.scopus2-s2.0-85114224288
dc.identifier.scopusqualityQ1
dc.identifier.startpage570en_US
dc.identifier.trdizinid521609
dc.identifier.urihttps://journals.tubitak.gov.tr/biology/issues/biy-21-45-si-1/biy-45-si-1-17-2105-73.pdf
dc.identifier.urihttps://hdl.handle.net/11468/7629
dc.identifier.volume5en_US
dc.identifier.wosWOS:000691376800017
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorOnay, Ahmet
dc.institutionauthorErtaş, Abdulselam
dc.institutionauthorYener, İsmail
dc.institutionauthorYılmaz, Mustafa Abdullah
dc.institutionauthorEkinci, Remzi
dc.institutionauthorBozhan, Nesrin
dc.institutionauthorİrtegün-Kandemir, Sevgi
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technical Research Councilen_US
dc.relation.ispartofTurkish Journal of Biology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAntiviralen_US
dc.subjectCannabidiolen_US
dc.subjectCannabinoidsen_US
dc.subjectCannabinoid systemen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.titleCannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy?en_US
dc.titleCannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy?
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Cannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy.pdf
Boyut:
3.16 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Eczacılık Fakültesi Temel Eczacılık Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu